Keywords

• Artemisinin
• Artemisinin powder
• 99% Artemisinin

Quick Details

• ProName: Baricitinib Powder Material Anti-Rheu...
• CasNo: 63968-64-9
• Molecular Formula: C15H22O5
• Appearance: white
• Application: Artemisia annua is used as antimalaria...
• DeliveryTime: 7-10 days
• PackAge: drum
• Port: Shanghai/Wuhan
• ProductionCapacity: 1000 Kilogram/Day
• Purity: 99
• Storage: room
• LimitNum: 1 Kilogram

Superiority

Baricitinib Powder Material  Anti-Rheumatism  

Product Name    Baricitinib 
Appearance    White Powder
CAS No.    1187594-09-7 
MF    C16H17N7O2S 

Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications called tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.  

Baricitinib (baricitinib) obtained FDA emergency authorization (EUA) to be used in combination with Redecivir to treat patients who require supplemental oxygen, intubation ventilation or extracorporeal membrane oxygenation, children over 2 years of age, or adult hospitalized patients with new coronary pneumonia or Suspected patient. The FDA emergency authorization is based on a clinical trial (ACTT-2) conducted by the National Institute of Allergy and Infectious Diseases (ACTT-2). Compared with radcivir monotherapy, baritinib is combined with radcivir.  

Details

Baricitinib Powder Material  Anti-Rheumatism  

Product Name    Baricitinib 
Appearance    White Powder
CAS No.    1187594-09-7 
MF    C16H17N7O2S 

Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications called tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.  

Baricitinib (baricitinib) obtained FDA emergency authorization (EUA) to be used in combination with Redecivir to treat patients who require supplemental oxygen, intubation ventilation or extracorporeal membrane oxygenation, children over 2 years of age, or adult hospitalized patients with new coronary pneumonia or Suspected patient. The FDA emergency authorization is based on a clinical trial (ACTT-2) conducted by the National Institute of Allergy and Infectious Diseases (ACTT-2). Compared with radcivir monotherapy, baritinib is combined with radcivir.